SLS Stock Price
SELLAS Life Sciences Group, Inc.
SLS stock price is $12.67 (+6.20% on the day), giving SELLAS Life Sciences Group, Inc. a market cap of $2.41B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
SLS Stock Overview
- Price
- $12.67
- Previous close
- $11.93
- Open
- $11.74
- Market cap
- $2.41B
- P/E ratio
- -89.6
- 52-week range
- $1.39 - $15.88
- 1-year price target
- $32.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSC
- MarketXLS Rank
- 39
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLS | $12.67 | +6.2% | 4.74M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get SELLAS Life Sciences Group, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW